Abstract
The main interest in mesenchymal stromal cells (MSCs) is correlated with their ability to suppress the proliferation of T lymphocytes induced by mitogenic agents and alloantigens which regulate the transplantation rejection. Moreover, MSCs are resistant to the CD8+ T lymphocyte cytotoxicity, they are able to inhibit the differentiation of dendritic cells responsible for the antigen presentation, the proliferation, and antibody production of B lymphocytes and they stimulate the formation of regulatory T cells. The mechanisms at the basis of MSCs activity need cell–cell interaction and the secretion of soluble molecules induced by the micro-environment. The inhibitory functions of MSCs involve several soluble molecules as hepatocyte growth factor, transforming growth factor-beta, interleukin-10 and -2, tumor necrosis factor-alpha, prostaglandin E2, indoleamine 2,3-dioxygenase (IDO), and soluble HLA-G antigens. A large consensus has been obtained on the immuno-modulatory role of IDO and HLA-G molecules.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Friedenstein AJ, Chailakhyan RK, Lalykina KS (1970) The development of fibroblast colonies in monolayer cultures of guinea pig bone marrow and spleen colonies. Cell Tissue Kinet 3:393–403
Prockop DJ (1997) Marrow stromal cells as stem cells for non-hematopoietic tissues. Science 276:71
Dominici M, Le Blank K, Prockop DI, Howartz E (2006) Position paper: minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8:315–317
Dexter TM (1979) Cell interactions in vitro. Cin Haematol 8:453–468
Castro-Malaspina H, Gay RE, Resnik G, Kapoor N, Meyers P, Chiarieri D, McKenzie S, Broxmeyer HE, Moore MA (1980) Characterization of human bone marrow fibroblast colony-forming cells (CFU-F) and their progeny. Blood 56:289–301
Tavassoli M, Friedenstein A (1983) Hemopoietic stromal microenvironment. Am J Haematol 15:196–203
Eaves AC, Eaves CJ (1988) Maintenance and proliferation control of primitive hemopoietic progenitors in long-term cultures of human marrow cells. Blood Cells 14:355–368
Owen M, Friedenstein AJ (1988) Stromal stem cells: marrow-derived osteogenic precursors. Ciba Found Symp 136:42
Wulf GG, Jackson KA, Goodell MA (2001) Somatic stem cell plasticity: current evidence and emerging concepts. Exp Hematol 29:1361–1370
Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR (1999) Multilineage potential of adult human mesenchymal stem cells. Science 284:143
Di Girolamo CM, Stokes D, Colter D, Phinney DG, Class R, Prockop DJ (1999) Propagation and senescence of human marrow stromal cells in culture: a simple colony-forming assay identifies samples with the greatest potential to propagate and differentiate. Br J Haematol 107:275–281
Reyes M, Lund T, Lenvik T, Aquiar D, Koodie L, Verfaillie CM (2001) Purification and ex vivo expansion of postnatal human marrow mesodermal progenitor cells. Blood 98:2615–2625
Colter DC, Sekiya I, Prockop DJ (2001) Identification of a subpopulation of rapidly self-renewing and multipotential adult stem cells in colonies of human marrow stromal cells. PNAS 98:7841–7845
Urbani S, Caporale R, Lombardini L, Bosi A, Saccaridi R (2006) Use of CFDA-SE for evaluating the in vitro proliferation pattern of human MSC. Cytotherapy 8:243–253
Taormin A, Brune JC, Olsson E, Valcich J, Neuman U, Olofsson T, Jacobsen SE, Scheding S (2009) Characterization of bone marrow derived MSC based on gene expression profiling of functionally defined MSC subsets. Cytotherapy 11:114–128
Majumdar MK, Keane-Moore M, Buyaner D et al (2003) Characterization and functionality of cell surface molecules on human mesenchymal stem cells. J Biomed Sci 10:228–241
Conget PA, Minguell JJ (1999) Phenotypical and functional properties of human bone marrow mesenchymal progenitor cells. J Cell Physiol 181:67–73
Beltrami AP, Cesselli D, Bergamin N, Marcon P, Rigo S, Puppato E, D’Aurizio F, Verardon R, Piazza S, Pignatelli A, Poz A, Baccaroni U, Damiani D, Fanin R, Mariuzzi L, Finato N, Masolini P, Burelli S, Belluzzi O, Schneider C, Beltrami CA (2007) Multipotent cells can be generated in vitro from several adult human organs (heart, liver, bone marrow). Blood 110:3438
Götherström C, West A, Liden J, Uzunel M, Lahesmaa R, Le Blanc K (2005) Differences in gene expression between human fetal liver and adult bone marrow mesenchymal stem cells. Haematologica 90:1017–1026
Simmons PJ, Torok-Storb B (1991) Identification of stromal precursors in human bone marrow by a novel monoclonal antibody, STRO-1. Blood 78:55–62
Campioni D, Lanza F, Moretti S, Dominaci M, Punturieri M, Pauli S, Hofmann T, Horwitz E, Castaldi GL (2003) Functional and immunophenotypic characteristics of isolated CD105+ and fibroblasts + mesenchymal cells from acute myeloid leukaemia: implication for their plasticity along endothelial lineage. Cytotherapy 5:66–79
Buhring HJ, Battula VL, Treml S, Schewe B, Kanz L, Vogel W (2007) Novel markers for the prospective isolation of human MSC. Ann N Y Acad Sci 1106:262–271
Deschaseux F, Charbord P (2000) Human marrow stromal precursors are α1 integrin subunit-positive. J Cell Physiol 184:319–325
Battula VL, Treml S, Bareiss PM, Gieseke F, Roelofs H, de Zwart P, Muller I, Schewe B, Skutella T, Fibbe WE, Kanz L, Buhring HJ (2009) Isolation of functionally distinct MSC cell subsets using antibodies aginst CD56, CD271 and mesenchymal stem cell antigen-1 (MSCA-1). Haematologica 94:173–184
Bhuring HJ, Kuci S, Conze T, Rathke G, Scherl-Mostageer M, Brummendorf TH, Schweifer N, Lammers R (2004) CDCP1 identifies a broad spectrum of normal and malignant stem/progenitor cell subsets of hematopoietic and non-hematopoietic origin. Stem Cells 22:334–343
SorrentinoA, Ferracin M, Castelli G, Biffoni M, Tomaselli G, Baiocchi M, Fatica A, Negrini M, Peschle C, Valtieri M (2008) Isolation and characterization of CD146+ multipotent mesenchymal stromal cells. Exp Haematol 36:1035–1046
Quirici N, Soligo D, Bossolasco P, Servida F, Lumini C, Delivers GL (2002) Isolation of bone marrow mesenchymal stem cells by anti-nerve growth factor receptor antibodies. Exp Haematol 30:783–791
Gang EJ, Bosnakovsky D, Figueiredo CA et al (2007) SSEA-4 identifies MSC from bone marrow. Blood 109:1743–1751
Mendez-Ferrer S, Michurina TV, Ferraro F, Mazloom AR, Macarthur BD, Lira SA, Scadden DT, Ma’ayan A, Enikopolov GN, Frenette PS (2010) Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature 466(7308):829–834
Tormin A, Li O, Brune JC, Walsh S, Schtz B, Ehinger M, Ditzel N, Kassem M, Scheding S (2011) CD146 expression on primary non-hematopoietic bone marrow stem cells is correlated with in situ localization. Blood 117:5067–5077
Martinez C, Hofman TJ, Marino R, Dominaci M, Horwitz EM (2007) Human bone marrow mesenchymal cells express the neural ganglioside GD2: a novel surface markers for the identification of MSC. Blood 109:4245–4248
Sordi V, Malosio ML, Marchesi F, Mercalli A, Melzi R, Giordano T, Belmonte N, Ferrari G, Leone BE, Bertuzzi F, Zerbini G, Allavena P, Bonifacio E, Piemonti L (2005) Bone marrow mesenchymal stem cells express a restricted set of functionally active chemokine receptors capable of promoting migration to pancreatic islet. Blood 106:419–425
Sanchez-Guijo FM, Blanco JF, Cruz G, Muntion S, Gomez M, Carrancio S, Lopez-Villar O, Barbado MV, Sanchez-Abarca LI, Blanco B, Brinon JG, Del Canizo MC (2009) Multiparametric comparison of mesenchymal stromal cells obtained from trabecular bone by using a novel isolation method with those obtained by iliac crest aspiration from the subjects. Cell Tissue Res 336(3):501–507
Landuyt KBV, Jones EA, McGonagle D, Luyten FP, Lories RJ (2010) Flow cytometric characterization of freshly isolated and cultured expanded human synovial cell population in patients with chronic arthritis. Arthr Res Ther 12:R15
Jones E, English A, Kinsey S et al (2006) Optimization of a flow cytometry-based protocol for detection and phenotypic characterization of multipotent mesenchymal stromal cells from human bone marrow. Cytometry Part B 70B:391–399
Bradford JA, Clarke ST (2011) Panel development for multicolor flow cytometry testing of proliferation and immunophenotype in h MSCs. Methods Mol Biol 698:367–385
Tabera S, Perez-Simon JA, Diez-Campelo M, Sanchez-Abarca LI, Blanco B, Lopez A, Benito A, Ocio E, Sanchez-Guijo FM, Canizo C, San Miguel JF (2008) The effect of mesenchymal stem cells on the viability, proliferation and differentiation of B-Lymphocytes. Haematologica 93:1301–1309
Meuleman N, Tondreau T, Delforge A, Dejeneffe M, Massy M, Libertalis M, Bron D, Lagneaux L (2006) Human marrow mesenchymal stem cell culture : serum-free medium allows better expansion than classical a-MEM medium. Eur J Haematol 76:309–316
Mueller I, Kordowich S, Holzwarth C, Spano C, Isensee G, Staiber A, Viebahn S, Gleseke F, Langer H, Gawaz MP, Horwitz EM, Conte P (2006) Animal serum-free culture conditions for isolation and expansion of multipotent mesenchymal stromal cells from human BM. Cytotherapy 8:437–444
Esposito MT, Di Noto R, Mirabelli P, Garrese M, Parisi S, Montanaro D, Del Vecchio L, Pastore L (2009) Culture conditions allow selection of different MSC progenitors from adult mouse bone marrow. Tissue Eng Part A 15:124
Sotiropoulou PA, Perez SA, Salagianni M, Baxevanis CN, Papamichail M (2006) Characterization of the optimal culture conditions for clinical scale production of human mesenchymal stem cells. Stem Cells 24:74–85
Kalz N, Ringe J, Holzwarth C, Chrabord P, Niemeyer M, Jacobs VR, Peschel C (2010) Novel markers of mesenchymal stem cells defined by genome-wide gene expression analysis of stromal cells from different sources. Exp Cell Res 316:2609–2617
Lee RH, Hsu SC, Munoz J, Jung JS, Lee NR, Pochampally R, Prockop DJ (2006) A subset of human rapidly-self renewing marrow stromal cells (MSCs) preferentially engraft in mice. Blood 107:2153–2161
Samuelsson H, Ringden O, Lönnies L, Le Blanc K (2009) Optimizing in vitro conditions for immunomodulation and expansion of mesenchymal stem cells. Cytotherapy 11:129–136
Grisendi G, Anneren C, Cafarelli L, Sternieri R, Veronesi E, Cervo GL, Luminari S, Maur M, Frassoldati A, Palazzi G, Otsuru S, Bambi F, Paolucci P, Conte PF, Horwitz E, Dominici M (2010) GMP-manufactured density gradient media for optimized mesenchymal stromal stem cell isolation and expansion. Cytotherapy 12:466–477
Bieback K, Kinzebach S, Karagianni M (2010) Translating research into clinical scale manufacturing of mesenchymal stromal cells. Stem Cells Int 2010:193519
Haniffa MA, Collin MP, Buckley CD, Dazzi F (2009) Mesenchymal stem cells: the fibroblasts’ new clothes? Haematologica 94:258–263
Chang HY, Chi JT, Dudoit S, Bondre C, van de Rijn M, Botstein D, Brown PO (2002) Diversity, topographic differentiation, and positional memory in human fibroblasts. Proc Natl Acad Sci U S A 99:12877–12882
Jin HJ, Park SK, Oh W, Yang YS, Kim SW, Choi SJ (2009) Down-regulation of CD105 is associated with multilineage differentiation in human umbilical cord derived-MSC. Biochem Biophys Res Comm 381:676–681
Kemp K, Morse R, Wexler S, Cox C, Mallam E, Hows J, Donaldson C (2010) Chemotherapy induce mesenchymal stem cell damage in patients with haematological malignancy. Ann Hematol 89:701–713
Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, Matteucci P, Grisanti S, Gianni AM (2000) Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 99:3838–3843
Le Blanc K, Tammik C, Rosendahl K, Zetterbergie E, Ringdén O (2003) HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal cells. Exp Hematol 31:890–896
Rizzo R, Campioni D, Stignani M, Melchiorri L, Bagnara GP, Bonsi L, Alviano F, Lanzoni G, Moretti S, Cuneo A, Lanza F, Baricordi OR (2008) A functional role for soluble HLA-G antigens in immune modulation mediated by mesenchymal stromal cells. Cytotherapy 10:364–375
Tse WT, Pendleton JD, Beyer WM, Egalka MC, Guinan EC (2003) Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplant 75:389–397
Meisel R, Zibert A, Laryea M, Gobel U, Daubener W, Dilloo D (2004) Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 103:4619–4621
Taylor MW, Feng G (1991) Relationship between interferon-gamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism. FASEB J 5(11):2516–2522
Munn DH, Sharma MD, Lee JR, Jhaver KG, Johnson TS, Keskin DB, Marshall B, Chandler P, Antonia S, Burgess R, Slingwff CL Jr, Mellor AL (2002) Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science 297:1867–1870
Terness P, Bauer TM, Rose L, Dufter C, Watzlik A, Simon H, Opelz G (2002) Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites. J Exp Med 196:447–457
Popp FC, Eggenhofer E, Renner P, Slowik P, Lang SA, Kaspar H, Geissler EK, Piso P, Schlitt HJ, Dahlke MH (2008) Mesenchymal stem cells can induce long-term acceptance of solid organ allografts in synergy with low-dose mycophenolate. Transpl Immunol 20(1–2):55–60
Spaggiari GM, Capobianco A, Abdelrazik H, Becchetti F, Mingari MC, Moretta L (2008) Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood 111(3):1327–1333
Spoerri PE, Caballero S, Wilson SH, Shaw LC, Grant MB (2003) Expression of IGFBP-3 by human retinal endothelial cell cultures: IGFBP-3 involvement in growth inhibition and apoptosis. Invest Ophthalmol Vis Sci 44(1):365–369
Baricordi OR, Stignani M, Melchiorri L, Rizzo R (2008) HLA-G and inflammatory diseases. Inflamm Allergy Drug Targets 7:67–74
Götherström C, West A, Liden J, Uzunel M, Lahesmaa R, Le Blanc K (2005) Difference in gene expression between human fetal liver and adult bone marrow mesenchymal stem cells. Haematol 90:1017–1026
Nasef A, Mathieu N, Chapel A, Frick J, François S, Mazurier C, Boutarfa A, Bouchet S, Gorin NC, Thierry D, Fouillard L (2007) Immunosuppressive effects of mesenchymal stem cells: involvement of HLA-G. Transplant 84(2):231–237
Selmani Z, Naji A, Zidi I, Favier B, Gaiffe E, Obert L, Borg C, Saas P, Tiberghien P, Rouas-Freiss N, Carosella ED, Deschaseaux F (2008) Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells. Stem Cells 2(1):212–222
Ning H, Yang F, Jiang M, Hu L, Feng K, Zhang J, Yu Z, Li B, Xu C, Li Y, Wang J, Hu J, Lou X, Chen H (2008) The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study. Leukemia 22:593–599
Rizzo R, Campioni D, Lanza F, Baricordi OR (2008) Cotransplantation of mesenchymal cells and a higher relapse rate: a role for HLA-G molecules? Leukemia 22:2273
Rizzo R, Lanzoni G, Stignani M, Campioni D, Alviano F, Ricci F, Tazzari PL, Melchiorri L, Scalinci SZ, Cuneo A, Bonsi L, Lanza F, Bagnara GP, Baricordi OR (2011) A simple method for identifying bone marrow mesenchymal stromal cells with a high immunosuppressive potential. Cytotherapy 13:523–527
Ivanova-Todorova E, Mourdjeva M, Kyurkchiev D, Bochev I, Stoyanova E, Dimitrov R, Timeva T, Yunakova M, Bukarev D, Shterev A, Tivchev P, Kyurkchiev S (2009) HLA-G expression is up-regulated by progesterone in mesenchymal stem cells. Am J Reprod Immunol 62(1):25–33
Lanza F, Campioni D, Moretti S, Ferrari L, Rizzo R, Baricordi R, Cuneo A (2007) Aberrant expression of HLA-DR antigen by bone marrow-derived mesenchymal stromal cells from patients affected by acute lymphoproliferative disorders. Leukemia 21:378–381
Bocelli-Tyndall C, Zajac P, Di Maggio N, Trella E, Benvenuto F, Iezzi G, Scherberich A, Barbero A, Schaeren S, Pistoia V, Spagnoli G, Vukcevik M, Martin I, Tyndall A (2010) Fibroblast growth factor 2 and Platelet-derived growth factor, but not platelet lysete, induce proliferation-dependent, functional class II major histocompatibility complex antigen in human mesenchymal stem cells. Arthritis Rheum 62:3815–3825
Campioni D, Rizzo R, Stignani M, Melchiorri L, Ferrari L, Rizzo R, Baricordi R, Cuneo A, Lanza F, Moretti S, Ferrari L, Alviano F, Russo A (2009) A decreased positivity for CD90 on human mesenchymal stromal cells (MSCs) is associated with a loss of immunosuppressive activity by MSCs. Cytometry 76(3):225–230
Kuci S, Kuci Z, Kreyemberg H, Deak E, Putsch K, Huenecke S, Amara C, Koller S, Rettinger E, Grez M, Koehl U, Latifi-Pupovci H, Henschler R, Tonn T, von Laer D, Kliengebiel T, Bader P (2010) CD271 antigen define a subset of multipotent stromal cells with immunosuppressive and lymphohematopoietic engraftment-promoting properties. Haematologica 95(4):651–659
Nasef A, Zhang YZ, Mazurier C, Bouchet S, Bensidhoum M, Francois S, Gorin NC, Lopez M, Thierry D, Fouillard L, Chapel A (2009) Selected STRO-1 enriched bone marrow stromal cells display a major suppressive effect on lymphocyte proliferation. Int J Lab Hematol 31:9–19
Krampera M, Franchini M, Pizzolo G, Aprili G (2007) Mesenchymal stem cells: from biology to clinical use. Blood Transfus 5:120–129
Schäfer R, Dominici M, Müller I, Horwitz E, Asahara T, Bulte JW, Bieback K, le Blanc K, Buhring HJ, Capogrossi MC, Dazzi F, Gorodetsky R, Henschler R, Handgretinger R, Kajstura J, K Luger P, Lange C, Luettichau I, Mertsching H, Schrezenmejer H, Sievert KD, Strunk D, Verfaillie C, Northoff H (2008) Basic research and clinical applications of non-hematopoietic stem cells. Cytotherapy 11:245–255 (4–5 April 2008, Tübingen, Germany)
Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, Lanino E, Sundberg B, Bernardo ME, Remberger M, Dini G, Egeler RM, Bacigalupo A, Fibbe W, Ringden O (2008) Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus host disease: a phase II study. Lancet 371:1579–1586
Horwitz EM, Gordon PL, Koo WKK et al (2002) Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: implications for cell therapy of bone. Proc Natl Acad Sci U S A 99:8932–8937
Almeida-Porada G, Flake AW, Glimp HA, Flake AW, Glimp HA, Zanjani ED (1999) Cotransplantation of stroma results in enhancement of engraftment and early expression of donor hematopoietic stem cells in utero. Exp Hematol 27:1569–1575
Devine SM, Cobbs C, Jennings M (2003) Mesenchymal stem cells distribute to a wide range of tissue following systemic infusion into nonhuman primates. Blood 101:2999–3001
Horwitz EM, Dominici M (2008) How do mesenchymal stromal cells exert their therapeutic benefit? Cytotherapy 10:771–774
Woodbury D, Schwarz EJ, Prockop DJ, Black IB (2000) Adult rat and human bone marrow stem cells differentiate into neurons. J Neurosci Res 61:223–229
Bouchez G, Sensebè L, Vourc’h P, Garreau L, Bodard S, Rico A, Guilloteau D, Charbord P, Besnard JC, Chalon S (2008) Partial recovery of dopaminergic pathway after graft of adult MSC in a rat model of Parkinson’s disease. Neurochem Int 52:1332–1342
Kalbermatten DF, Pierer G, Terenghi G, Kingham PJ (2010) Regeneration potential and survival of transplanted undifferentiated adipose tissue-derived stem cells in peripheral nerve conduits. J Plast Reconstr Aesthet Surg 12:e811–e817
Kingham PJ, Mantovani C, Terenghi G (2011) Stem cell and neuron co-cultures for the study of nerve regeneration. Methods Mol Biol 695:115–127
Lu P, Blesch A, Tuszynski MH (2004) Induction of bone marrow stem cells into neurons: differentiation, transdifferentiation or artefact? J Neurosci Res 77:174–191
Planat-Bénard V, Menard C, Andrè M, Puceat M, Perez A, Garcia-Verdugo JM, Penicaud L, Casteilla L (2004) Spontaneous cardiomyocyte differentiation from adipose tissue stroma cells. Circ Res 94:223–229
Rossini A, Frati C, Lagrasta C, Graiani G, Scopece A,Cavalli S, Musso E, Baccarini M, Di Segni M, Fagnoni F, Germani A, Quaini E, Mayr M, Qingbo Xu, Barbuti A, Di Francesco, Pompilio G, Quaini F, Gaetano C, Capogrossi MC (2011) Human cardiac and bone marrow stromal cells exhibit distinctive properties related to their origin. Cardiovascular Res 89:650–660
Gnecchi M, He H, Melo GM, Noiseux N, Morello F, De Boer R, Zhang L, Pratt RE, Dzau VJ, Ingwall JS (2009) Early beneficial effects of bone marrow derived mesenchymal cells overexpressing Akt on cardiac metabolism after myocardial infarction. Stem Cells 27:971–979
Mirza A, Hyvelin JM, Rochefort GY, Lermusiaux P, Antier D, Awede B, Bonnet P, Domenech J, Eder V (2008) Undifferentiated MSC seeded on a vascular prosthesis contribute to the restoration of vascular wall. J Vasc Surg 47:1313–1321
Mauritz C, Martens A, Rojas SV, Schnick T, Rathert C, Schecker N, Menke S, Glage S, Zweigerdt R, Haverich A, Martin U, Kutschaka I (2011) Induced pluripotent stem cell (iPSC)-derived Flk-1 progenitor cells engraft, differentiate, and improve heart function in a mouse model of acute myocardial infarction. Eur Heart J. doi:10.1093/eurheart/ehr166
Lee KD, Kuo TK, Whang-Peng J, Chung YF, Lin CT, Chou SH, Chen JR, Chen YP, Lee OK (2004) In vitro hepatic differentiation of human MSC. Hepatology 40:1275–1284
Wang HS, Shyu JF, Shen WS, Hsu HC, Chi TC, Chen CP, Huang SW, Shyr YM, Tang KT, Chen TH (2011) Transplantation of insulin producing cells derived from umbilical cord stromal mesenchymal cells to treat NOD mice. Cell Transplant 20(3):455–466
Lange C, Togel F, Ittrich H, Clayton F, Nolte- Ernesting C, Zander AR, Westen Felder C (2005) Administered MSC enhance recovery from ischemia/reperfusion-induced acute renal failure in rats. Kidney Int 68:1613–1617
Bussolati B (2011) Stem cells for organ repair: support or replace? Biomatter 1:95
Kode JA, Mukherjee S, Joglekar MV, Hardikar AA (2009) Mesenchymal stem cells: immunobiology and in immunomodulation and tissue regeneration. Cytotherapy 11:377–391
Zachos T, Diggs A, Weisbrode S, Bartlett J, Bertone A (2007) Mesenchymal stem cells mediated gene delivery of bone morphogenetic protein-2 in an articular fracture model. Mol Ther 15:1543–1550
Caplan AI (2007) Adult MSC for tissue engineering versus regenerative medicine. J Cell Physiol 213:341–347
Barti-Juhasz H, Mihalik R, Nagy K, Grisendi G, Dominici M, Petak I (2011) Bone marrow derived MSC transduced with full length human TRAIL repress the growth of rhabdomyosarcoma cells in vitro. Haematologica 96:e21
Liechty KW, MacKenzie TC, Shaaban AF, Radu A, Moseley AM, Deans R, Marshak DR, Flake AW (2000) Human mesenchymal stem cells engraft and demonstrate site-specific differentiation after in utero transplantation in sheep. Nat Med 6:1282–1286
Ball LM, Bernardo ME, Roelofs H, Lankester A, Cometa A, Egeler RM, Locatelli F, Fibbe WE (2007) Cotransplantation of ex vivo expanded MSC accelerates lymphocyte recovery and may reduce risk of graft failure in haploidentical hematopoietic stem cell transplantation. Blood 110:2764–2767
Lazarus HM, Koc ON, Devine SM, Curtin P, Marziaz RT, Holland HK, Shpall EJ, McCarthy P, Atkinson K, Cooper BW, Gerson SL, Laughlin MJ, Loberizia FR, Moseley AB, Bacigalupo A (2005) Cotransplantation of HLA-identical sibling culture expanded MSC and HSC in hematologic malignancy patients. Biol Blood Marrow Transpl 11:389–398
Le Blanc K, Ringden O (2005) Immunobiology of human mesenchymal stem cells and future use in hematopoietic stem cell transplantation. Biol Blood Marrow Transpl 11:321–334
Sensebè L, Krampera M, Schrezenmeier H, Bourin P, Giordano R (2010) Mesenchymal stem cell for clinical application. Vox Sang 98:93–107
Vianello F, Dazzi F (2008) Mesenchymal stem cells for graft-versus host disease: a doible-egde sword? Leukemia 22:463–465
Tolar J, Villeneuve P, Keating A (2011) Mesenchymal stromal cells for graft-versus-host disease. Hum Gene Ther 22:257–262
Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, lanino E, Sundberg B, Bernardo ME, Remberger M, Dini G, Egeler RM, Bacigalupo A, Fibbe W, Ringden O (2008) Mesenchymal stem cells for treatment of steroid resistant, severe, acut GVHD: a phase II study. Lancet 363:1439–1441
Kucerova L, Matuskova M, Hlubinova K, Altanerova V, Altaner C (2010) Tumor cell behaviour modulation by mesenchymal stromal cells. Mol Cancer 9:129
Prockop D, Brenner M, Fibbe W (2010) Defining the risk of therapies with MSC. Cytotherapy 12:576–578
Marini FC (2009) Commentary: the complex love-hate relationship between mesenchymal stromal cells and tumors. Cytotherapy 11:375–376
Djouad F, Plence P, Bony C (2003) Immunosuppressive effect of mesenchymal stem cells favours tumor growth in allogeneic animals. Blood 102:3837–3844
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science + Bussines Media, LLC
About this chapter
Cite this chapter
Lanza, F., Campioni, D., Mauro, E., Pasini, A., Rizzo, R. (2012). Immunosuppressive Properties of Mesenchymal Stromal Cells. In: Baharvand, H., Aghdami, N. (eds) Advances in Stem Cell Research. Stem Cell Biology and Regenerative Medicine. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-61779-940-2_15
Download citation
DOI: https://doi.org/10.1007/978-1-61779-940-2_15
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-61779-939-6
Online ISBN: 978-1-61779-940-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)